Latest News-Ascentage Pharma Mediaroom_Page

ASH 2022 | Ascentage Pharma to Present Data of Olverembatinib (HQP1351) in Three Oral Reports, Including the First Dataset from the First US Study, at the ASH Annual Meeting

SUZHOU, China, and ROCKVILLE, Md., Nov. 3, 2022 /PRNewswire/ -- Ascentage Pharma (6855.HK), a glob...

2022-11-04 03:32 1816

AASLD 2022 | Ascentage Pharma to Announce Results from First-in-Human Study of IAP Antagonist APG-1387 in an Oral Report at the AASLD Annual Meeting

SUZHOU, China and ROCKVILLE, Md., Oct. 19, 2022 /PRNewswire/ -- Ascentage Pharma (6855.HK), a globa...

2022-10-20 07:16 1245

Ascentage Pharma Announces Phase I/II Data of Olverembatinib (HQP1351) Published in the Journal of Hematology & Oncology, Further Validating the Drug's Best-in-Class Potential

SUZHOU, China and ROCKVILLE, Md., Sept. 21, 2022 /PRNewswire/ -- Ascentage Pharma (6855.HK), a glob...

2022-09-21 22:49 1396

Ascentage Pharma Announces 2022 Interim Results

SUZHOU, China and ROCKVILLE, Md. , Aug. 26, 2022 /PRNewswire/ -- Ascentage Pharma (6855.HK), a glob...

2022-08-27 00:47 12806

Ascentage Pharma and Tanner Pharma Group Initiate a Global Innovative Named Patient Program

SUZHOU, China and ROCKVILLE, Md. and CHARLOTTE, N.C., July 25, 2022 /PRNewswire/ --Ascentage Pharma...

2022-07-25 21:59 2114

Ascentage Pharma Announces Clinical Trial Application for Olverembatinib (HQP1351) Approved in Canada

SUZHOU, China and ROCKVILLE, MD, July 21, 2022 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global...

2022-07-22 07:59 2070

Ascentage Pharma and Innovent Announce the China NMPA Accepted and Granted Priority Review Designation to a New Drug Application for Olverembatinib for the Treatment of Drug-Resistant CML

SUZHOU, China, ROCKVILLE, Md. and SAN FRANCISCO, July 19, 2022 /PRNewswire/ -- Ascentage Pharma (68...

2022-07-20 00:15 1760

Ascentage Pharma Announces IND Clearance by the US FDA for First-in-Human Study of Novel EED Inhibitor APG-5918

SUZHOU, China and ROCKVILLE, Md., June 29, 2022 /PRNewswire/ -- Ascentage Pharma (6855.HK), a globa...

2022-06-30 10:41 1536

EHA 2022 | Ascentage Pharma Releases Encouraging Results of Bcl-2 Inhibitor Lisaftoclax (APG-2575) in Chinese Patients with Relapsed/Refractory Non-Hodgkin Lymphoma

SUZHOU, China, and ROCKVILLE, MD, June 12, 2022 /PRNewswire/ -- Ascentage Pharma (6855.HK), a globa...

2022-06-13 07:45 3661

ASCO 2022 | Ascentage Pharma Releases for the First Time Results of its FAK/ALK/ROS1 inhibitor APG-2449 Demonstrating Safety and Efficacy in Patients with Advanced NSCLC

SUZHOU, China, and ROCKVILLE, MD, June 7, 2022 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global...

2022-06-08 08:00 1370

ASCO 2022 | Ascentage Pharma Releases Updated Data Demonstrating Lisaftoclax's (APG-2575) Therapeutic Potential in Patients with R/R CLL/SLL

SUZHOU, China and ROCKVILLE, Md., June 7, 2022 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global...

2022-06-08 08:00 1458

ASCO 2022 | Ascentage Pharma Releases Updated Results Demonstrating the Therapeutic Potential of Alrizomadlin (APG-115) plus Pembrolizumab in Patients with Solid Tumors who Progressed on Immunotherapies

SUZHOU, China, and ROCKVILLE, Md., June 6, 2022 /PRNewswire/ -- scentage Pharma (6855.HK), a global...

2022-06-07 11:30 1770

ASCO 2022 | The First Dataset of Olverembatinib (HQP1351) in Patients with GIST Demonstrates Therapeutic Potential with a Clinical Benefit Rate of 83.3%

SUZHOU, China, and ROCKVILLE, Md., June 6, 2022 /PRNewswire/ -- Ascentage Pharma (6855.HK), a globa...

2022-06-07 11:28 1563

ASCO 2022 | Ascentage Pharma Presents Updated Results from Multiple Clinical Studies Demonstrating Rapid Progress in Global Clinical Development

SUZHOU, China, and ROCKVILLE, Md., May 26, 2022 /PRNewswire/ -- Ascentage Pharma (6855.HK), a globa...

2022-05-27 10:02 2141

Ascentage Pharma Announces Preclinical Data Demonstrating Olverembatinib's Therapeutic Potential in Treating COVID-19 Published in EMBO Molecular Medicine

SUZHOU, China and ROCKVILLE, Md., May 18, 2022 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global...

2022-05-18 22:06 2165

ASCO 2022 | Ascentage Pharma to Present Data from Seven Clinical Studies at the 2022 American Society of Clinical Oncology Annual Meeting

SUZHOU, China, and ROCKVILLE, MD, April 27, 2022 /PRNewswire/ -- Ascentage Pharma (6855.HK), a glob...

2022-04-28 08:18 1393

AACR 2022 | Ascentage Pharma Presents Latest Results from Six Preclinical Studies at AACR Annual Meeting 2022

SUZHOU, China and ROCKVILLE, Md., April 13, 2022 /PRNewswire/ -- Ascentage Pharma (6855.HK), a glob...

2022-04-14 08:28 1687

Ascentage Pharma's MDM2-p53 Inhibitor Alrizomadlin (APG-115) Granted Rare Pediatric Disease Designation by the US FDA for the Treatment of Neuroblastoma

SUZHOU, China, and ROCKVILLE, MD, March 21, 2022 /PRNewswire/ -- Ascentage Pharma (6855.HK), a glob...

2022-03-22 09:15 1483

Ascentage Pharma Announces 2021 Annual Results with Commercialization Programs Going Full Steam Ahead

SUZHOU, China and ROCKVILLE, Md., March. 21, 2022 /PRNewswire/ -- Ascentage Pharma (6855.HK), a glo...

2022-03-21 23:11 2486

Ascentage Pharma Announces First Patient Dosed in China in the Pivotal Phase II Study of Lisaftoclax (APG-2575) in R/R CLL/SLL

SUZHOU, China, and ROCKVILLE, Md., Mar. 14, 2022 /PRNewswire/ -- Ascentage Pharma (6855.HK), a glob...

2022-03-15 14:52 1429